Ongoing studies focus on EGFR-TKI alone or combination chemotherapy as first line therapy in benefit population.
正在进行的临床研究聚焦于优势人群EGFR -TKI一线治疗或联合化疗的研究。
Ongoing studies focus on EGFR-TKI alone or combination chemotherapy as first line therapy in benefit population.
正在进行的临床研究聚焦于优势人群EGFR -TKI一线治疗或联合化疗的研究。
应用推荐